SK bioscience began its domestic supply of Novavax’s updated COVID-19 vaccine, which targets the XBB.1.5 variant, Dec. 18, as part of the country’s effort to provide a wider range of vaccine choices in addition to mRNA-based vaccines, according to the vaccine maker, Sunday.